Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Avestar Capital LLC

Avestar Capital LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 12.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,210 shares of the pharmaceutical company’s stock after purchasing an additional 237 shares during the quarter. Avestar Capital LLC’s holdings in Vertex Pharmaceuticals were worth $899,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Arlington Trust Co LLC lifted its holdings in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the period. Fortitude Family Office LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Baystate Wealth Management LLC lifted its holdings in Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares during the period. Quest Partners LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $33,000. Finally, NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 7,073 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $17,920,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 7,073 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $17,920,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Charles F. Wagner, Jr. sold 3,250 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $454.79, for a total value of $1,478,067.50. Following the sale, the chief financial officer now owns 50,387 shares in the company, valued at approximately $22,915,503.73. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,888 shares of company stock valued at $5,361,977. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.4 %

Shares of NASDAQ:VRTX traded up $1.92 during trading on Thursday, hitting $443.05. The company’s stock had a trading volume of 974,391 shares, compared to its average volume of 1,211,883. The company has a market capitalization of $114.33 billion, a PE ratio of 28.75, a P/E/G ratio of 2.29 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $457.66. The business has a 50 day moving average price of $416.16 and a two-hundred day moving average price of $408.60.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 earnings per share. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on VRTX. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Barclays boosted their price objective on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Royal Bank of Canada boosted their price objective on Vertex Pharmaceuticals from $417.00 to $424.00 and gave the company a “sector perform” rating in a research report on Tuesday, May 7th. Oppenheimer reiterated an “outperform” rating and set a $500.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. Finally, StockNews.com cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $432.18.

Check Out Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.